Development of organometallic ruthenium(II) anticancer (RAPTA) drugs

A review. The systematic development of the RAPTA family of organometallic ruthenium(II) anticancer drugs contg. a monodentate 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane ligand and a h6-arene ligand is described.


Published in:
CHIMIA, 61, 4, 140-142
Year:
2007
Other identifiers:
Laboratories:




 Record created 2008-03-09, last modified 2018-01-28


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)